Research Article
Use of Response Surface Methodology in the Formulation and Optimization of Bisoprolol Fumarate Matrix Tablets for Sustained Drug Release
Table 1
The formulation chart for all proposed trial formulations of bisoprolol fumarate matrix tablets.
| Formulation codes | Drug (mg) | Calcium alginate (mg) () | HPMC K4M (mg) () | Carbopol 943 (mg) () | Lactose (mg) | MCC (mg)a | Mg-stearate (mg) |
| F-1 | 20 | 15 (−1) | 0 (−1) | 0 (−1) | 70 | 20 | 10 | F-2 | 20 | 30 (+1) | 20 (+1) | 20 (+1)
| 70 | 20 | 10 | F-3 | 20 | 30 (+1) | 0 (−1) | 0 (−1) | 70 | 20 | 10 | F-4 | 20 | 30 (+1) | 20 (+1) | 0 (−1) | 70 | 20 | 10 | F-5 | 20 | 15 (−1) | 20 (+1) | 20 (+1) | 70 | 20 | 10 | F-6 | 20 | 15 (−1) | 0 (−1) | 20 (+1) | 70 | 20 | 10 | F-7 | 20 | 30 (+1) | 0 (−1) | 20 (+1) | 70 | 20 | 10 | F-8 | 20 | 15 (−1) | 20 (+1) | 0 (−1) | 70 | 20 | 10 |
|
|
aMCC: Microcrystalline cellulose; , , and represent the main effects (factors); (+1): higher value and (−1): lower value.
|